ArtVentive Medical Group Inc. announced enrollment in the ongoing ArtVentive EOS Endoluminal Occlusion System, OCCLUDE post-market surveillance study.

A single-center study noted that treatment with Cardiac Dimensions’ Carillon Mitral Contour System resulted in significant improvement of functional mitral regurgitation (FMR), a condition that can increase the symptoms of heart failure. The study was recently published in the Journal of Invasive Cardiology.

Using clot-busting drugs to clear blood from the brain’s ventricles may be the first effective strategy to decrease mortality for a type of catastrophic bleeding stroke, according to new phase-3 clinical trial results.

February 23, 2016 — WITS(MD), a provider of medical image workflow solutions, announced a company name change to ImageMoverMD. The new name is part of a re-branding initiative to align the company’s name with its current solutions and future strategy. The name change is effective immediately.

The U.S. Food and Drug Administration (FDA) approved an expanded indication trial for low-risk surgical patients using Medtronic’s CoreValve Evolut R System transcatheter aortic valve replacement (TAVR) system. Patients with aortic stenosis, who are at a low surgical mortality risk as determined by a heart team, will be enrolled in the trial.

February 22, 2016 — A new study found that survival rates from cardiac arrest decrease the higher up in a high-rise building a person lives.

"Cardiac arrests that occur in high-rise buildings pose unique barriers for 911-initiated first responders," said Ian Drennan, lead author of the study published in the Canadian Medical Association Journal.

TherOx Inc. announced the first patient has been enrolled in an Investigational Device Exemption (IDE) confirmatory study of its second-generation system that delivers supersaturated oxygen (SSO2) therapy for reduction of infarct size after an acute myocardial infarction (AMI). This study is being conducted to support a premarket approval submission to the U.S. Food and Drug Administration (FDA).

Intact Vascular, Tack Endovascular System
Bard_Lutonix DEB before
Boston Scientific, Eluvia
Shockwave Medical’s Lithoplasty balloon catheters that use lithotripsy pulsatile mechanical energy bursts to shatter the calcium, rather than radial force of the balloon.
hockwave Medical, Lithoplasty. An example of Lithoplasty in action, with the original calcified lesion on the left, followed by what it looked like after treatment without the use of high pressure angioplasty to dilate the vessel.
Covidien's EverFlex stent is one of the most recent cleared by the FDA.
CSI Diamondback atherectomy to treat PAD. The CSI Diamondback atherectomy burr uses a diamond coating to grind away calcium on vessel walls.

It is estimated that more than 10 million people in the United States are affected by peripheral arterial disease (PAD),[1] and these patients represent a new source to boost cath lab volumes. However, very high rates of restenosis in PAD lesions have necessitated the development of new tools to improve vessel patency rates.
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now